Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Nov
12
Today In Oncology
Metastatic Uveal Melanoma Darovasertib/Crizotinib Evaluated as First-Line Targeted Therapy
Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases
American Cancer Society Updates Prostate Cancer Screening Guideline
Childhood Cancers Survival Gains Reveal Progress and Persistent Disparities
Immunochemotherapy Improves Event-Free Survival in Borderline Resectable or Locally Advanced Pancreatic Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo